The approval came from the Drugs Controller General of India.
The product "Sofosbuvir+Velpatasvira" will be marketed and distributed under the brand name "Velasof" in India by Hetero Healthcare Ltd, the company said in a statement.
Sofosbuvir+Velpatasvir is a two-drug fixed dose combination product that contains 400mg of Sofosbuvir and 100mg of Velpatasvir in a single tablet.
This fixed-dose combination is the generic version of Gilead's brand Epclusa, approved by US FDA to treat patients with chronic hepatitis C genotype 1 to 6, the statement said.
The product will be launched under the non-exclusive licensing agreement with Gilead Sciences Inc, which allows to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.
This website uses cookies.
